Neumora Halts Navacaprant Development After Phase 3 Depression Trials Fail
Neumora stopped navacaprant after failed depression trials, cut 35% jobs, shares fell, but keeps advancing 3 other drugs.
/ 5 items
#NMRA↓
William Blair Upgrades Neumora Therapeutics to Outperform on Promising Alzheimer's Agitation Data
William Blair analyst upgrades Neumora Therapeutics to Outperform after strong early data for its Alzheimer's agitation drug NMRA-511, seeing big potential in a huge market.
Neumora Shows Promise with New Alzheimer's Agitation Treatment
Neumora Therapeutics (NMRA) announces positive Phase 1b results for NMRA-511, a new drug candidate showing clinically meaningful improvements in Alzheimer's disease agitation symptoms with favorable safety profile.
RBC Capital Upgrades Neumora Therapeutics to Outperform
RBC Capital raises Neumora Therapeutics to Outperform, citing new growth opportunities beyond neurology and promising early data in multiple markets.
Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results
Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.